Newsroom press releases

15/12/23 - 17:38

Diasorin Board of Directors approves 2024-2027 Business Plan (294.02 KB)

Financial Data

06/11/23 - 15:44

Diasorin and Gilead Sciences collaborate to develop a Fully Automated Diagnostic Assay for Hepatitis Delta Virus on Diasorin’s LIAISON XL® for the U.S. Market (506.97 KB)

Products Immunodiagnostic

03/11/23 - 15:51

Third Quarter results confirm guidance for Fiscal Year 2023 (822.89 KB)

Financial Data

24/10/23 - 15:03

Diasorin unveils its new Corporate identity and launches the new Group website: www.diasorin.com (574.08 KB)

Other

27/07/23 - 14:27

Update 2023 Annual Calendar of Corporate Events (104.1 KB)

Other

27/07/23 - 13:18

Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed (598.06 KB)

Financial Data

17/07/23 - 7:03

DiaSorin launches the LIAISON® Legionella Urinary Ag assay in all countries accepting the CE Mark to improve diagnosis of legionnaires’ disease (510.4 KB)

Products Immunodiagnostic

03/07/23 - 11:48

Suspension of the effectiveness of the disqualifying accessory administrative sanction imposed by CONSOB to the Chief Executive Officer Mr. Carlo Rosa (102.52 KB)

Other

13/06/23 - 15:18

DiaSorin launches the LIAISON® B·R·A·H·M·S MR-proADM™ assay in all countries accepting the CE Mark (578.05 KB)

Products Immunodiagnostic

07/06/23 - 14:40

Communication of total amount of voting rights (7 June 2023) (141.14 KB)

Financial Disclosures

05/06/23 - 21:58

Administrative sanctions imposed by CONSOB in connection with the alleged breach to disclose obligations relating to inside information. Action for annulment. (107.91 KB)

Other

26/05/23 - 7:10

DIASORIN CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM (159.38 KB)

Acquisition / Partnership

09/05/23 - 11:56

Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023 (675.79 KB)

Financial Data

28/04/23 - 12:52

Shareholders' Meeting 2023 (373.48 KB)

Other

27/03/23 - 15:52

Update 2023 Annual Calendar of Corporate Events (483.89 KB)

Financial Disclosures

27/03/23 - 14:38

Dividend coupon date correction (493.46 KB)

Financial Data

27/03/23 - 13:35

REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE (334.51 KB)

Financial Data

17/03/23 - 22:05

DiaSorin Simplexa COVID Flu assay received U.S. FDA 510(K) clearance (155.02 KB)

Products Molecular

28/02/23 - 16:06

Sale of Flow Cytometry and Imaging business from DiaSorin to Cytek® Biosciences completed (130.89 KB)

Acquisition / Partnership

13/02/23 - 22:03

CYTEK BIOSCIENCES TO ACQUIRE FLOW CYTOMETRY AND IMAGING BUSINESS FROM DIASORIN (165.22 KB)

Acquisition / Partnership

07/02/23 - 12:01

Update 2023 Annual Calendar of Corporate Events (288.3 KB)

Financial Disclosures